← Leaderboards
Andrius Kazlauskas
Schepens Eye Research Institute
$15,558,315
Attributed
$15,558,315
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$15,558,315 · 8
By mechanism
R01$13,942,712 · 5
R03$577,716 · 1
R21$528,650 · 1
T32$509,237 · 1
Top collaborators
No co-investigators on record.
Most similar at Schepens Eye Research Institute
Same institution · by research overlap
- Gisela Velez$1,185,217
- Ann E Elsner$9,473,451
- Hetian Lei$1,001,032
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseMolecularPreventEventOperative Surgical ProceduresGrowth FactorGrantCellsProliferative VitreoretinopathyRetinal DetachmentAcuteIn VitroSignal TransductionBlood VesselsEnzymesVascular Endothelial Growth FactorsPlatelet Derived Growth FactorIn Vitro ModelProliferative Diabetic RetinopathyProductionGrowth Factor ReceptorsFoundationsPhospholipase CWestern Blottings
Grant awards (40)
Anti-VEGF-mediated barrier closure$384,970
R01 · FY2024 · EY · contact PI
Anti-VEGF-mediated barrier closure$384,970
R01 · FY2023 · EY · contact PI
Anti-VEGF-mediated barrier closure$373,421
R01 · FY2022 · EY · contact PI
Anti-VEGF-mediated barrier closure$373,610
R01 · FY2021 · EY · contact PI
Anti-VEGF-mediated barrier closure$399,750
R01 · FY2020 · EY · contact PI
PDGF and PVR$500,516
R01 · FY2014 · EY · contact PI
Can FDA-approved agents protect from PVR?$237,650
R21 · FY2014 · EY · contact PI
Can FDA-approved agents protect from PVR?$291,000
R21 · FY2013 · EY · contact PI
PDGF and PVR$587,632
R01 · FY2012 · EY · contact PI
PDGF and PVR$587,632
R01 · FY2011 · EY · contact PI
Signaling events that control the fate of existing vessels$457,380
R01 · FY2011 · EY · contact PI
PDGF and PVR$597,094
R01 · FY2010 · EY · contact PI
Signaling events that control the fate of existing vessels$476,438
R01 · FY2010 · EY · contact PI
PDGF and PVR$588,565
R01 · FY2009 · EY · contact PI
Signaling events that control the fate of existing vessels$481,250
R01 · FY2009 · EY · contact PI
Signaling events that control the fate of existing vessels$471,625
R01 · FY2008 · EY · contact PI
PDGF and Proliferative Vitreoretinopathy$466,290
R01 · FY2008 · EY · contact PI
PDGF and Proliferative Vitreoretinopathy$475,806
R01 · FY2007 · EY · contact PI
Signaling events that control the fate of existing vessels$291,501
R01 · FY2007 · EY · contact PI
Understanding vessel regression$190,322
R03 · FY2007 · EY · contact PI
PDGF and PVR$478,485
R01 · FY2006 · EY · contact PI
Understanding vessel regression$191,394
R03 · FY2006 · EY · contact PI
PDGF and PVR$490,000
R01 · FY2005 · EY
Understanding vessel regression$196,000
R03 · FY2005 · EY
PDGF and Proliferative Vitreoretinopathy$490,000
R01 · FY2004 · EY
THE ROLE OF SFK IN PDGF SIGNALING$339,962
R01 · FY2004 · CA
Training Program in the Molecular Bases of Eye Disease$258,849
T32 · FY2004 · EY
A GENE THERAPY-BASED APPROACH TO PREVENT PVR$465,000
R01 · FY2003 · EY
THE ROLE OF SFK IN PDGF SIGNALING$339,962
R01 · FY2003 · CA
PDGF RECEPTOR ASSOCIATED PROTEINS IN SIGNALING$297,201
R01 · FY2003 · GM
Training Program in the Molecular Bases of Eye Disease$250,388
T32 · FY2003 · EY
A GENE THERAPY-BASED APPROACH TO PREVENT PVR$435,000
R01 · FY2002 · EY
THE ROLE OF SFK IN PDGF SIGNALING$339,962
R01 · FY2002 · CA
PDGF RECEPTOR ASSOCIATED PROTEINS IN SIGNALING$297,201
R01 · FY2002 · GM
A GENE THERAPY-BASED APPROACH TO PREVENT PVR$435,000
R01 · FY2001 · EY
THE ROLE OF SFK IN PDGF SIGNALING$339,962
R01 · FY2001 · CA
PDGF RECEPTOR ASSOCIATED PROTEINS IN SIGNALING$297,201
R01 · FY2001 · GM
A GENE THERAPY-BASED APPROACH TO PREVENT PVR$405,000
R01 · FY2000 · EY
THE ROLE OF SFK IN PDGF SIGNALING$316,941
R01 · FY2000 · CA
PDGF RECEPTOR ASSOCIATED PROTEINS IN SIGNALING$277,385
R01 · FY2000 · GM